This article refers to:
Yeung J, Holinstat M. Newer agents in antiplatelet therapy: a review. Journal of Blood Medicine. 2012;3:33–42.
An error was made on page 37, section GPVI receptor antagonists, in the above paper. The company currently moving Revacept® through clinical development is in fact advanceCor GmbH (Martinsried, Germany) and not ABX-CRO/ Medifacts GmbH (Goerlitz, Saxony, Germany).